GlassScriptPhysician profile
Emily George
NPI 1093284309
$963.55
in general payments reported to CMS, 2019-2025
15 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.58 · 2023: $88.58 · 2024: $552 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $83.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.66 |
| Education | $83.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.50 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.67 | 2023-2025 | Entyvio, Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.45 | 2024-2025 | Xifaxan |
| Celltrion USA INC. | $83.31 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $67.52 | 2024-2025 | Resmetirom, Rezdiffra |
| Braintree Laboratories, INC. | $59.33 | 2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $51.82 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $41.81 | 2023-2024 | Linzess |
| Genzyme Corporation | $34.44 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $24.49 | 2024 | Dupixent |
| Ardelyx, INC. | $22.64 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $21.44 | 2023 | Talicia |
| Novo Nordisk INC | $19.30 | 2024 | Wegovy |
| Neos Therapeutics, LP | $18.58 | 2022 | |
| Cranial Technologies, INC | $16.25 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.